ANN ARBOR, Michigan — Early stage health investor Arboretum Ventures has added George Dunbar, former chief executive of Michigan biotech company Aastrom Biosciences Inc., as a partner.
Dunbar, who stepped down from Aastrom last month, will help the venture firm uncover new investment opportunities and work with executives from Arboretum’s portfolio companies, according to Tim Peterson, the firm’s managing director. Publicly traded Aastrom is a stem cell firm developing treatments for cardiovascular disease. The company has several products in clinical trials.
Founded in 2002, Arboretum manages about $97 million in capital. The firm had a major exit last year when one of its portfolio companies, University of Michigan spin-off HandyLab, was acquired by Becton, Dickinson and Co. for $275 million. HandyLab‘s “Jaguar” device helps doctors identify infections. Another recent exit for Arboretum happened in October 2008, when Johnson & Johnson purchased HealthMedia Inc. (pdf), which develops web-based, wellness-coaching software.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Arboretum’s current portfolio includes St. Louis-based telemedicine-services company Advanced ICU Care, Ann Arbor-based Accuri Cytometers, which develops cell-analysis products and Chagrin Falls, Ohio-based Cervilenz, which is developing a device to help obstetricians identify women at risk for preterm birth.
